Advertisement
Screener

WHITEHAWK THERAPEUTICS, INC. (WHWK) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

WHITEHAWK THERAPEUTICS, INC. Selling, General and Administrative Expense

WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Selling, General and Administrative Expense of $5.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06

  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $5.22M, a 12.19% decline year-over-year.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $6.29M, a 50.92% decline year-over-year.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $5.87M, a 46.92% decline year-over-year.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $5.20M, a 27.62% decline year-over-year.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $29.82M, a 18.85% decline from fiscal 2024.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $36.75M, a 17.51% decline from fiscal 2023.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $44.55M, a 10.88% increase from fiscal 2022.
  • WHITEHAWK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $40.18M, a 117.04% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 month
2026-06-30$5.22M
10-Q · filed 2026-08-06
$11.51M
10-Q · filed 2026-08-06
$17.37M
derived: sum of 3 quarters · filed 2026-08-06
$22.57M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$6.29M
10-Q · filed 2026-05-07
$12.16M
derived: sum of 2 quarters · filed 2026-05-07
$17.36M
derived: sum of 3 quarters · filed 2026-05-07
$23.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$5.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$11.07M
derived: sum of 2 quarters · filed 2026-03-12
$17.01M
derived: sum of 3 quarters · filed 2026-08-06
$29.82M
10-K · filed 2026-03-12
2025-09-30$5.20M
10-Q · filed 2025-11-06
$11.14M
derived: sum of 2 quarters · filed 2026-08-06
$23.96M
10-Q · filed 2025-11-06
$35.01M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$5.94M
10-Q · filed 2026-08-06
$18.75M
10-Q · filed 2026-08-06
$29.81M
derived: sum of 3 quarters · filed 2026-08-06
$36.99M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$12.81M
10-Q · filed 2026-05-07
$23.87M
derived: sum of 2 quarters · filed 2026-05-07
$31.05M
derived: sum of 3 quarters · filed 2026-05-07
$38.94M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$11.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$18.24M
derived: sum of 2 quarters · filed 2026-03-12
$26.13M
derived: sum of 3 quarters · filed 2026-03-12
$36.75M
10-K · filed 2026-03-12
2024-09-30$7.19M
10-Q · filed 2025-11-06
$15.08M
derived: sum of 2 quarters · filed 2025-11-06
$25.70M
10-Q · filed 2025-11-06
$36.04M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$7.89M
10-Q · filed 2025-08-07
$18.51M
10-Q · filed 2025-08-07
$28.86M
derived: sum of 3 quarters · filed 2025-08-07
$40.08M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$10.62M
10-Q · filed 2025-05-08
$20.96M
derived: sum of 2 quarters · filed 2025-05-08
$32.19M
derived: sum of 3 quarters · filed 2025-05-08
$43.96M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$10.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
$21.57M
derived: sum of 2 quarters · filed 2025-03-28
$33.34M
derived: sum of 3 quarters · filed 2025-03-28
$44.55M
10-K · filed 2025-03-28
2023-09-30$11.22M
10-Q · filed 2024-11-06
$23.00M
derived: sum of 2 quarters · filed 2024-11-06
$34.20M
10-Q · filed 2024-11-06
$45.31M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$11.78M
10-Q · filed 2024-08-07
$22.98M
10-Q · filed 2024-08-07
$34.09M
derived: sum of 3 quarters · filed 2024-08-07
$44.01M
derived: sum of 4 quarters · filed 2024-08-07
2023-03-31$11.21M
10-Q · filed 2024-05-08
$22.31M
derived: sum of 2 quarters · filed 2024-05-08
$32.23M
derived: sum of 3 quarters · filed 2024-05-08
$42.23M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31$11.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13
$21.02M
derived: sum of 2 quarters · filed 2024-03-13
$31.03M
derived: sum of 3 quarters · filed 2024-03-13
$40.18M
10-K · filed 2024-03-13
2022-09-30$9.91M
10-Q · filed 2023-11-08
$19.92M
derived: sum of 2 quarters · filed 2023-11-08
$29.07M
10-Q · filed 2023-11-08
$38.79M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$10.01M
10-Q · filed 2023-08-09
$19.15M
10-Q · filed 2023-08-09
$28.87M
derived: sum of 3 quarters · filed 2023-08-09
$36.27M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31$9.15M
10-Q · filed 2023-05-10
$18.87M
derived: sum of 2 quarters · filed 2023-05-10
$26.27M
derived: sum of 3 quarters · filed 2023-05-10
$27.10M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31$9.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
$17.12M
derived: sum of 2 quarters · filed 2023-03-29
$17.95M
derived: sum of 3 quarters · filed 2023-03-29
$18.51M
10-K · filed 2023-03-29
2021-09-30$7.40M
10-Q · filed 2022-11-09
$8.23M
derived: sum of 2 quarters · filed 2022-11-09
$8.79M
10-Q · filed 2022-11-09
2021-06-30$830.00K
10-Q · filed 2022-08-10
$1.39M
10-Q · filed 2022-08-10
2021-03-31$563.00K
10-Q · filed 2022-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
MACROGENICS INC (MGNX)United States$0.242B-20.11